Our Recommendations
- Guidelines forPrevention and Management of Stroke (2019)
- Alzheimer's Disease International. The Global Voice on Dementia (2019)
- Management of physical health conditions in adults with severe mental disorders (2018)
- mhGAP Intervention Guide Mental Health Gap Action Programme Version 2.0 for mental, neurological and substance use disorders in non-specialized health settings (2016)
- Atlas: country resources for neurological disorders 2004: results of a collaborative study of the World Health Organization and the World Federation of Neurology (2004)
New Publications
- Dementia in Latin America and the Caribbean: Prevalence, Incidence, Impact, and Trends over Time (2023)
- Demenz und Migration (2023)
- iSupport for dementia: training and support manual for carers of people with dementia (2022)
- Manual para el entrenamiento y apoyo de cuidadores de personas con demencia: manual completo (2022)
- Por el Sendero de Epilepsia Ges 2016 Niños y Adultos (2016)
Filter
225
Featured
Recommendations
15
New Publications
11
Language
Document type
No document type
203
Training Material
7
Fact sheets
4
Studies & Reports
3
Guidelines
3
Manuals
2
Strategic & Response Plan
2
Resource Platforms
1
Countries / Regions
Russia
23
Ukraine
18
Eastern Europe
14
Western and Central Europe
12
Africa
12
India
9
Global
5
Latin America and the Carribbean
4
Uganda
3
South Sudan
3
Germany
3
Nigeria
2
Congo, Democratic Republic of
2
Nepal
2
Syria
2
Estonia
2
USA
1
China
1
Brazil
1
Chile
1
South–East Asia Region
1
Asia
1
Iran
1
Australia
1
Authors & Publishers
Publication Years
Category
Public Health
16
Clinical Guidelines
10
Countries
8
Capacity Building
4
Women & Child Health
1
Bull World Health Organ 2013;91:773–783 | doi: http://dx.doi.org/10.2471/BLT.13.118422
(Submitted: 15 February 2013 – Revised version received: 21 June 2013 – Accepted: 22 June 2013 – Published online: 20 August 2013)
Доказательной базой для рекомендаций являются публикации, вошедшие в базы данных PubMed/MEDLINE, данные международных согласительных документов по болезни Альцгеймера:...
Цель настоящего доклада — повысить осведомленность о деменции как
одной из приоритетных проблем общественного здравоохранения, сформу-
лировать подход к этой п...
African Health Sciences 2013; 13(2): 219 - 232 http://dx.doi.org/10.4314/ahs.v13i2.4
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 19, No. 9, September 2013
Neurology in Africa
recommended
The whole book has 50.3 MB!!!!
To download chapter by chapter:
http://www.uib.no/cih/en/resources/neurology-in-africa
Africa is a vast continent and neurological disorders are a common cause of disability and death. This practical neurology textbook is specifically written for Sub-Saharan Africa....
Lancet 2012; 380: 1193–1201
Series: Epilepsy 2
www.jogh.org • doi: 10.7189/jogh.02.020405 ~ December 2012 • Vol. 2 No. 2 • 020405
Epilepsies: diagnosis and management
recommended
Clinical guideline | Published: 11 January 2012 | nice.org.uk/guidance/cg137
BMC Medicine201210:107
https://doi.org/10.1186/1741-7015-10-107© Katchanov and Birbeck; licensee BioMed Central Ltd. 2012
Received: 10 July 2012Accepted: 24 September 2012Published: 24 September 2012
In 2011, the World Health Organization’s (WHO) mental health Gap Action Programme (mhGAP) r...
Q10: For carers of people with dementia, does respite care when compared to care as usual, produce benefits/harm in the specified outcomes?
Q9: For carers of people with dementia, do interventions (psychoeducational, cognitive-behavioural therapy counseling/case management, general support, training of caregivers, multi-component interventions and miscellaneous interventions) when compared to placebo/comparator, produce benefits/harm in...
Q8: For people with dementia, what is the role of a medical review (including comorbid physical and mental conditions and medication use)?
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q6: Can dementia be diagnosed at first or second level care by non-specialist health care providers? What should be the assessment process for the diagnosis of dementia?
Q7: For people with dementia, who should be told of the diagnosis and how should the diagnosis be delivered?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
